123 Main Street, New York, NY 10001
The Co-Dx Logix Smart COVID-19 test kit is an in vitro diagnostic test that uses our patented Co-Primers™ technology for the qualitative detection of the RNA from SARS-CoV-2 coronavirus that causes (COVID-19).
The test operates using a single step real-time reverse transcriptase polymerase chain reaction (RT-PCR) process in lower respiratory tract fluids (e.g. bronchoalveolar lavage, sputum, tracheal aspirate), and upper respiratory tract fluids (e.g. nasopharyngeal and oropharyngeal swabs) from patients who meet the clinical criteria (e.g. signs and symptoms) for COVID-19.
Click here to read the Company’s regulatory bulletin on the ability of our suite of Co-Dx Logix Smart COVID-19 diagnostics to detect all known strains of SARS-CoV-2.
The Co-Dx Logix Smart COVID-19 test kit is available to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests, or by similarly qualified non-U.S. laboratories.
Qualitative real-time RT-PCR test for detection of the SARS-CoV-2 gene RdRp from individuals suspected by their healthcare provider of having COVID-19
Lower respiratory tract fluids (branchoalveolar lavage – BAL, sputum, and tracheal aspirate) and upper respiratory tract fluids (nasopharyngeal and oropharyngeal swabs)
Qualified and trained clinical laboratory personnel instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures
No microorganism in the in silico analysis has revealed ≥ 80% homology between the cross-reactivity microorganisms, including the ones of relevance listed below.
IT DOES NOT cross-react with the following microorganisms: SARS-CoV, MERS-CoV, Human coronaviruses (HCoV-229E, HCoV-OC43, HCoV-NL63, HCoVHKU1), Adenovirus, influenza A H3N2, Novel influenza A H1N1, influenza B, influenza C, Metapneumovirus (hMPV), Parainfluenza 1, Parainfluenza 2, Parainfluenza 3, Parainfluenza 4, Respiratory syncytial virus (subtype A), Respiratory syncytial virus (subtype B), Parechovirus, Candida albicans, Corynebacterium diphtheriae, Legionella non-pneumophila, Bacillus anthracis, Moraxella catarrhalis, Neisseria elongata, Neisseria meningitides, Pseudomonas aeruginosa, Staphylococcus Aureus, Streptococcus salivarius, Leptospirosis, Chlamydia psittaci, Coxiella burnetti (Q-Fever), Staphylococcus epidermidis, Enterovirus, Rhinovirus, Haemophilus influenzae, Mycobacterium tuberculosis, Bordetella parapertussis, Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila.
* Calculations are based on 90 negative and 90 positive replicates of contrived samples using synthetic SARS-CoV-2 RNA template, and the following reagent which was deposited by the U.S. Center for Disease Control and Prevention and obtained through BEI Resources, NAID, NIH: Genomic RNA from SARS-related Coronavirus 2, Isolate USA-WAI/2020, NR-52285
Contact us for more information about the Co-Dx Logix Smart COVID-19 test kit.
Every test from Co-Dx is designed to be easy to use.
In February 2020, the Co-Dx Logix Smart COVID-19 test kit received CE marking approval, the principle regulatory clearance allowing the test to be sold as an in vitro diagnostic (IVD) for the diagnosis of COVID-19 in European Union states and other markets that accept a CE-IVD mark as valid regulatory approval.
On April 3, 2020, the Co-Dx Logix Smart COVID-19 test kit obtained Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to be used for the diagnosis of SARS-CoV-2: FDA Letter of Authorization
Co-Diagnostics, Inc.
2401 S. Foothill Dr. Suite D
Salt Lake City, UT 84109 USA
1 (801) 438-1036
info@co-dx.com
Co-Dx, Co-Primers, Logix Smart, Co-Dx Box, PCR Home, PCR Pro, and Vector Smart, and unless otherwise specified, all other product and service names appearing in this Internet site are trademarks owned by Co-Diagnostics, Inc., its subsidiaries or affiliates. No use of any Co-Diagnostic trademark, trade name, or trade dress in this site may be made without the prior written authorization of Co-Diagnostics, except to identify the product or services of the company.
TaqMan is a trademark of Roche Molecular Systems.